Wedbush has taken a bullish stance on SpaceX by initiating coverage with an Outperform rating and a $190 price target. Multiple outlets, including Investor’s Business Daily, Yahoo Finance, and Barron’s, highlight Dan Ives’s optimism toward Starlink and potential AI-driven growth.

Wedbush analysts have lowered their 2029 earnings projection for Revolution Medicines, Inc. (NASDAQ: RVMD) from $1.47 to $1.23 per share. The updated report signals a more reserved stance on the biotech firm’s long-term performance outlook.

Analysts at Wedbush project that Telix Pharmaceuticals could achieve an earnings per share of $0.89 by 2028. The research note, released on August 21st, underscores the potential growth trajectory for the pharmaceutical company in the coming years.